$472.57
Today
as of Jul 22, 16:25 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 2
● 22
▼ 1
Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating
Overview
52-week range
$362
$508
76% of range
Avg surprise (last 3)
+3.4%
Avg reaction (last 2)
+0.6%
50% positive
Latest IV / EM
34%
EM ±2.5% · $483 · Jul 24
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 4, 2026 | Mar/2026 | $3.95 | $3.69 | +7.0% | +11.3% | +1.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $4.20 | — | — | — | — | financials |
| Mon Aug 4, 2025 | Jun/2025 | $4.00 | $3.74 | +7.0% | — | — | earnings |
| Mon May 5, 2025 | Mar/2025 | $3.55 | $3.69 | -3.8% | — | -0.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $4.01 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-13.92 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $4.21 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $3.97 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $3.52 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 3, 2026 | Jun/2026 | AMC | $4.30 | $4.00 | +7.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $393M | — | $415M | $408M | $363M | — | $393M | $372M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $1.14B | — | $1.19B | $1.15B | $630M | — | $1.12B | $-3.51B |
| Net income | $1.03B | — | $1.08B | $1.03B | $646M | — | $1.05B | $-3.59B |
| EPS (diluted) | $4.02 | — | $4.20 | $3.99 | $2.49 | — | $4.01 | $-13.92 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.49B | $5.08B | $4.94B | $4.97B | $4.67B | $4.57B | $5.24B | $4.58B |
| Inventory | $1.77B | $1.69B | $1.63B | $1.50B | $1.36B | $1.21B | $1.08B | $915M |
| Total current assets | $11.73B | $11.20B | $10.57B | $10.43B | $10.01B | $9.60B | $9.80B | $8.94B |
| Total assets | $26.48B | $25.64B | $24.86B | $24.04B | $22.88B | $22.53B | $22.24B | $20.13B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $7.12B | $6.98B | $7.54B | $6.86B | $6.38B | $6.12B | $6.61B | $5.36B |
| Total equity | $19.36B | $18.67B | $17.32B | $17.18B | $16.50B | $16.41B | $15.63B | $14.77B |